Caris Life Sciences (CAI) Registration Filing summary

Company overview and business model

• Develops AI-driven precision medicine solutions, focusing on comprehensive molecular profiling for oncology and other chronic diseases.

• Offers both tissue-based (MI Profile) and blood-based (Caris Assure) molecular profiling solutions, leveraging whole exome and transcriptome sequencing.

• Maintains one of the largest clinico-genomic datasets in oncology, with over 6.5 million tests and 849,000 cases profiled as of March 31, 2025.

• Partners with over 100 biopharma companies and 96-member Precision Oncology Alliance for research and drug development.

• Business model includes clinical testing, biopharma R&D services, and data licensing.

Financial performance and metrics

• 2024 revenue: $412.3 million, up 34.7% from $306.1 million in 2023; Q1 2025 revenue: $120.9 million, up 49.9% YoY.

• Net losses: $281.9 million in 2024 and $341.4 million in 2023; Q1 2025 net loss: $102.6 million.

• Adjusted EBITDA: $(189.6) million in 2024, $(255.3) million in 2023; Q1 2025: $(36.2) million.

• Cash, cash equivalents, and short-term marketable securities: $33.4 million as of March 31, 2025; $400 million in term loan debt outstanding.

• Free cash flow: $(253.6) million in 2024, $(298.4) million in 2023.

Use of proceeds and capital allocation

• Estimated net proceeds of $364.6 million (or $420.4 million if underwriters' option exercised) at $17.00/share IPO price.

• Proceeds to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• $5 million allocated for anticipated tax withholding and remittance obligations related to RSU settlements.

• May use a portion for acquisitions or investments in complementary products, technologies, or businesses.